FDA Authorizes First Digital Treatment For Symptoms Of Schizophrenia

Click Therapeutics, Inc. announced the U.S. Food and Drug Administration (FDA) clearance of Motivista, a smartphone-based prescription digital therapeutic, on October 5, 2026. It is the first FDA-authorized treatment specifically indicated for negative symptoms of schizophrenia, including low motivation, reduced ability to experience pleasure, and social withdrawal. The treatment is intended to supplement existing outpatient care for adults with schizophrenia.

Click Therapeutics is preparing for broader commercial availability and working with state Medicaid programs and other payers to establish coverage through the pharmacy benefit.

Motivista is intended for adults 18 years of age and older with schizophrenia . . .